



**E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES
NON-GAAP RECONCILIATIONS: 2008 - 2013
(UNAUDITED)**

Note: Included within is unaudited supplemental data and non-GAAP reconciliations for full years 2008 - 2013. Information for years 2010 - 2013 has previously been published as part of unaudited supplemental data supporting our 2013 Quarterly Earnings Release financials. Years 2008 and 2009 have been revised by management to reflect the current reporting basis solely for historical comparison purposes.

<u>INDEX</u>	<u>PAGE</u>
SEGMENT SALES	1
SEGMENT PRETAX OPERATING INCOME	2
SEGMENT OPERATING EARNINGS	3
SIGNIFICANT ITEMS BY SEGMENT - PRETAX OPERATING INCOME	4
RECONCILIATION OF NON-GAAP MEASURES	5 - 6

Note: Operating earnings are defined as earnings from continuing operations (GAAP) excluding "significant items" and "non-operating pension and other post-employment benefit (OPEB) costs". Management believes that an analysis of operating earnings, a "non-GAAP" measure, is meaningful to investors because it provides insight with respect to ongoing operating results of the company. Such measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance.

E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

SEGMENT SALES (UNAUDITED)

(dollars in millions)

SEGMENT SALES	Year <u>2013</u>	Year <u>2012</u>	Year <u>2011</u>	Year <u>2010</u>	Year <u>2009</u>	Year <u>2008</u>
Agriculture	11,739	10,426	9,166	7,845	7,069	6,549
Electronics & Communications	2,549	2,701	3,173	2,764	1,918	2,194
Industrial Biosciences	1,224	1,180	705	-	-	-
Nutrition & Health	3,473	3,422	2,460	1,240	1,218	1,403
Performance Chemicals	6,703	7,188	7,794	6,322	4,964	6,035
Performance Materials	6,468	6,447	6,815	6,287	4,768	6,425
Safety & Protection	3,884	3,825	3,934	3,364	2,811	3,733
Other	<u>6</u>	<u>5</u>	<u>40</u>	<u>194</u>	<u>158</u>	<u>160</u>
Total Segment Sales	<u>36,046</u>	<u>35,194</u>	<u>34,087</u>	<u>28,016</u>	<u>22,906</u>	<u>26,499</u>
Elimination of Transfers	<u>(312)</u>	<u>(382)</u>	<u>(406)</u>	<u>(316)</u>	<u>(225)</u>	<u>(330)</u>
CONSOLIDATED NET SALES	<u><u>35,734</u></u>	<u><u>34,812</u></u>	<u><u>33,681</u></u>	<u><u>27,700</u></u>	<u><u>22,681</u></u>	<u><u>26,169</u></u>

E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

SEGMENT PRETAX OPERATING INCOME (UNAUDITED)

(dollars in millions)

SEGMENT PRETAX OPERATING INCOME (PTOI)	Year <u>2013</u>	Year <u>2012</u>	Year <u>2011</u>	Year <u>2010</u>	Year <u>2009</u>	Year <u>2008</u>
Agriculture	2,132	1,669	1,566	1,326	1,180	1,006
Electronics & Communications	203	222	438	520	99	211
Industrial Biosciences	170	159	2	-	-	-
Nutrition & Health	305	270	76	60	81	18
Performance Chemicals	924	1,778	2,114	1,223	568	604
Performance Materials	1,281	1,121	1,079	1,084	259	94
Safety & Protection	694	562	661	589	275	601
Other	<u>(372)</u>	<u>(474)</u>	<u>(344)</u>	<u>(286)</u>	<u>(169)</u>	<u>(186)</u>
	5,337	5,307	5,592	4,516	2,293	2,348
Pharmaceuticals	<u>32</u>	<u>62</u>	<u>289</u>	<u>489</u>	<u>1,037</u>	<u>1,025</u>
TOTAL SEGMENT PRETAX OPERATING INCOME	<u><u>5,369</u></u>	<u><u>5,369</u></u>	<u><u>5,881</u></u>	<u><u>5,005</u></u>	<u><u>3,330</u></u>	<u><u>3,373</u></u>

E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

SEGMENT OPERATING EARNINGS (UNAUDITED)

(dollars in millions)

SEGMENT OPERATING EARNINGS	Year <u>2013</u>	Year <u>2012</u>	Year <u>2011</u>	Year <u>2010</u>	Year <u>2009</u>	Year <u>2008</u>
Agriculture	2,483	2,138	1,791	1,376	1,180	1,011
Electronics & Communications	334	259	438	512	136	248
Industrial Biosciences	169	162	81	-	-	-
Nutrition & Health	299	319	202	60	80	35
Performance Chemicals	998	1,814	2,114	1,213	622	660
Performance Materials	1,297	1,225	1,032	1,068	267	404
Safety & Protection	690	620	661	584	320	698
Other	<u>(377)</u>	<u>(348)</u>	<u>(316)</u>	<u>(287)</u>	<u>(167)</u>	<u>(155)</u>
	5,893	6,189	6,003	4,526	2,438	2,901
Pharmaceuticals	<u>32</u>	<u>62</u>	<u>289</u>	<u>489</u>	<u>1,037</u>	<u>1,025</u>
TOTAL SEGMENT OPERATING EARNINGS	<u><u>5,925</u></u>	<u><u>6,251</u></u>	<u><u>6,292</u></u>	<u><u>5,015</u></u>	<u><u>3,475</u></u>	<u><u>3,926</u></u>

E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

SIGNIFICANT ITEMS BY SEGMENT - PRETAX OPERATING INCOME (UNAUDITED)

(dollars in millions)

SEGMENT PRETAX IMPACT OF SIGNIFICANT ITEMS	Year <u>2013</u>	Year <u>2012</u>	Year <u>2011</u>	Year <u>2010</u>	Year <u>2009</u>	Year <u>2008</u>
Agriculture	(351)	(469)	(225)	(50)	-	(5)
Electronics & Communications	(131)	(37)	-	8	(37)	(37)
Industrial Biosciences	1	(3)	(79)	-	-	-
Nutrition & Health	6	(49)	(126)	-	1	(17)
Performance Chemicals	(74)	(36)	-	10	(54)	(56)
Performance Materials	(16)	(104)	47	16	(8)	(310)
Safety & Protection	4	(58)	-	5	(45)	(97)
Pharmaceuticals	-	-	-	-	-	-
Other	5	(126)	(28)	1	(2)	(31)
TOTAL SIGNIFICANT ITEMS BY SEGMENT - PRETAX	<u>(556)</u>	<u>(882)</u>	<u>(411)</u>	<u>(10)</u>	<u>(145)</u>	<u>(553)</u>

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

(dollars in millions)

	Year <u>2013</u>	Year <u>2012</u>	Year <u>2011</u>	Year <u>2010</u>	Year <u>2009</u>	Year <u>2008</u>
RECONCILIATION OF OPERATING EARNINGS TO INCOME FROM CONTINUING OPERATIONS AFTER INCOME TAXES						
Operating Earnings (ex. Pharma)	3,611	3,526	3,602	2,753	1,070	1,541
Pharma Net Income ^(a)	21	40	188	318	674	666
Operating Earnings	3,632	3,566	3,790	3,071	1,744	2,207
Net Income Attributable to Noncontrolling Interests	14	25	40	19	17	4
Non-Operating Pension & OPEB (Costs) / Credits - After-tax	(360)	(439)	(361)	(352)	(90)	250
Significant Items - After-tax - (Charge) / Benefit	(423)	(680)	(237)	3	(99)	(378)
Income From Continuing Operations After Income Taxes	<u>2,863</u>	<u>2,472</u>	<u>3,232</u>	<u>2,741</u>	<u>1,572</u>	<u>2,083</u>

^(a) Pharma net income assumes a 35% tax rate.**RECONCILIATION OF SEGMENT OPERATING EARNINGS TO SEGMENT PTOI**

Adjusted Segment Operating Earnings (ex. Pharma) ^(b)	5,144	5,451	5,353	3,968	1,895	2,273
Add: Pharma	32	62	289	489	1,037	1,025
Add: Corporate Expenses ^(c)	749	738	650	558	543	628
Segment Operating Earnings	5,925	6,251	6,292	5,015	3,475	3,926
Significant Items included in Segment PTOI	(556)	(882)	(411)	(10)	(145)	(553)
Segment PTOI	<u>5,369</u>	<u>5,369</u>	<u>5,881</u>	<u>5,005</u>	<u>3,330</u>	<u>3,373</u>

^(b) Includes allocation of certain corporate expenses.^(c) Represents total corporate expenses excluding significant items and estimate of DuPont Performance Coatings residual costs.

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

	<u>Year 2013</u>	<u>Year 2012</u>	<u>Year 2011</u>	<u>Year 2010</u>	<u>Year 2009</u>	<u>Year 2008</u>
SEGMENT PTOI MARGIN % (PTOI / Segment Sales) ⁽¹⁾						
Agriculture	18.2%	16.0%	17.1%	16.9%	16.7%	15.4%
Electronics & Communications	8.0%	8.2%	13.8%	18.8%	5.2%	9.6%
Industrial Biosciences	13.9%	13.5%	0.3%	n/m	n/m	n/m
Nutrition & Health	8.8%	7.9%	3.1%	4.8%	6.7%	1.3%
Performance Chemicals	13.8%	24.7%	27.1%	19.3%	11.4%	10.0%
Performance Materials	19.8%	17.4%	15.8%	17.2%	5.4%	1.5%
Safety & Protection	17.9%	14.7%	16.8%	17.5%	9.8%	16.1%
Segment PTOI Margin % (ex. Pharma)	14.8%	15.1%	16.4%	16.1%	10.0%	8.9%
TOTAL SEGMENT PTOI MARGIN %	<u>14.9%</u>	<u>15.3%</u>	<u>17.3%</u>	<u>17.9%</u>	<u>14.5%</u>	<u>12.7%</u>
SEGMENT OPERATING EARNINGS MARGIN % (Operating Earnings / Segment Sales) ⁽¹⁾						
Agriculture	21.2%	20.5%	19.5%	17.5%	16.7%	15.4%
Electronics & Communications	13.1%	9.6%	13.8%	18.5%	7.1%	11.3%
Industrial Biosciences	13.8%	13.7%	11.5%	n/m	n/m	n/m
Nutrition & Health	8.6%	9.3%	8.2%	4.8%	6.6%	2.5%
Performance Chemicals	14.9%	25.2%	27.1%	19.2%	12.5%	10.9%
Performance Materials	20.1%	19.0%	15.1%	17.0%	5.6%	6.3%
Safety & Protection	17.8%	16.2%	16.8%	17.4%	11.4%	18.7%
Segment Operating Earnings Margin % (ex. Pharma)	16.3%	17.6%	17.6%	16.2%	10.6%	10.9%
Adjusted Segment Operating Earnings Margin % (ex. Pharma) ⁽²⁾	14.3%	15.5%	15.7%	14.2%	8.3%	8.6%
TOTAL SEGMENT OPERATING EARNINGS MARGIN %	<u>16.4%</u>	<u>17.8%</u>	<u>18.5%</u>	<u>17.9%</u>	<u>15.2%</u>	<u>14.8%</u>

(1) Segment PTOI & Operating Earnings Margin %'s for Pharmaceuticals and Other are not presented separately above as they are not meaningful.

(2) Includes allocation of certain corporate expenses. See page 5 for specific details.